Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
Cullinan plans approval push for NSCLC drug after ph. 2 win
Cullinan has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the data close to its chest for now.
James Waldron
Jan 29, 2025 6:15am
Merck discontinues development of 2 late-stage cancer assets
Dec 16, 2024 5:39pm
iTeos drops one of 3 clinical assets from pipeline
Dec 12, 2024 3:10pm
Chasing Merck, BioNTech, DualityBio post first data on ADC
Dec 6, 2024 9:07am
AstraZeneca, Daiichi share data behind Dato-DXd do-over
Dec 6, 2024 5:21am
Roche's TIGIT prospect fails another phase 3 lung cancer test
Nov 26, 2024 4:11am
